Dr. Adelman is a Managing Partner at venBio Partners. Dr. Adelman has a 30-year history of founding, investing in, and managing companies in the life sciences sector. Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both private and public companies across three venture capital funds. Dr. Adelman has co-founded a number of biotechnology companies. Dr. Adelman led venBio’s investment into Aragon Pharmaceuticals where he was a member of the Board of Directors until the company’s acquisition by Johnson & Johnson. He also led venBio’s investment into Seragon Pharmaceuticals where he was a member of the Board of Directors until the company’s acquisition by Genentech/Roche. Dr. Adelman is a member of the Board of Directors of Solstice Biologics, Heart Metabolics, Metacrine, and Precision Biosciences.
Biologics, Heart Metabolics, Metacrine, and Precision Biosciences.